Michael Yee, RBC Capital Markets, and Michael King, JMP Securities, look back at a very rough year for biotech stocks and discuss whether the sector is primed to take off.
While the markets are mostly lower following the Fed's rate hike decision, the Nasdaq biotech ETF IBB holds gains. CNBC's Jackie DeAngelis reports.
Jim Cramer explains the relationship between Apple and the Federal Reserve, and why it could benefit from a rate hike.
Beaten-up biotech stocks could fall further, according to one technical analyst who sees trouble in the charts.
Health-care stocks haven't gotten the green light many expected from Hillary Clinton's election loss.
CNBC's Meg Tirrell speaks with Celgene CEO Mark Alles at the American Society of Hematology about the company's immunotherapy partnerships and the upcoming Trump administration.
Ana Gupte, Leerink Partners, and Leonard Yaffe, StocDoc Partners, discuss stocks poised to win amid Trump's healthcare reform.
In the likely repeal of the Affordable Care Act, these health-care stocks should perform well, according to some analysts.
If they're right, the average lifespan of 79 years will be a thing of the past, and humans could live for decades longer.
Jim Cramer reflects on the stunning victory of Donald Trump, and how it will impact the stocks that lead the charge in the market.
Boris Schlossberg, Managing Director of FX Strategy, BK Asset Management, and Ari Wald, Oppenheimer, look at the post-election market surge.
Using hedge fund analytics tool Kensho, we looked at the correlation of all the stocks in the S&P 500 to the dollar-peso over the last three months.
Jim Cramer says investors love certainty more than Hillary Clinton and breaks down the winners of earnings season.
The IBB fell nearly 11 percent this month and could be headed lower.
Jefferies shares its favorite biotech stock ideas to pick up amid the recent share price weakness due to Hillary Clinton's rising poll numbers.
Chris Raymond, Raymond James analyst, discusses how to trade the biotech sell-off amid election season.
Jim Cramer says uncertainty surrounding a Democratic win for the White House puts drug stocks in the danger zone.
Shares of Ligand Pharmaceuticals plunged 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late-stage study.
CNBC contributor Mike Khouw discusses why he sees Celgene as a "very attractive trade."
The "Fast Money" traders debated whether it's time to pile into the biotech sector after the sector gained 3 percent on Monday.